loading
Precedente Chiudi:
$34.32
Aprire:
$34.68
Volume 24 ore:
87,525
Relative Volume:
0.53
Capitalizzazione di mercato:
$976.28M
Reddito:
-
Utile/perdita netta:
$-69.47M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-73.92M
1 W Prestazione:
+6.93%
1M Prestazione:
+43.90%
6M Prestazione:
+92.83%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$33.84
$36.09
Intervallo di 1 settimana:
Value
$31.63
$36.09
Portata 52W:
Value
$14.42
$38.93

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name
Nome
Lenz Therapeutics Inc
Name
Telefono
858-925-7000
Name
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
LENZ's Discussions on Twitter

Confronta LENZ con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
LENZ 35.50 976.28M 0 -69.47M -73.92M 0.00
VRTX 450.97 116.38B 10.63B -479.80M -1.35B 13.33
REGN 738.00 82.09B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.14B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.25B 3.30B -501.07M 1.03B 11.54

Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie

pulisher
Nov 20, 2024

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - MSN

Nov 20, 2024
pulisher
Nov 15, 2024

LENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3%Here's Why - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - The Malaysian Reserve

Nov 14, 2024
pulisher
Nov 12, 2024

LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year HighWhat's Next? - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences | LENZ Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - Yahoo Finance

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 EPS Estimate for LENZ Therapeutics Boosted by Analyst - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Has Bullish Outlook for LENZ FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 07, 2024

Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

Form 424B3 LENZ Therapeutics, Inc. - StreetInsider.com

Nov 06, 2024
pulisher
Nov 06, 2024

LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Employ Inc. Announces Promotion of Stephanie Manzelli to Chief Human Resources Officer - The Manila Times

Nov 06, 2024
pulisher
Oct 31, 2024

LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag

Oct 31, 2024
pulisher
Oct 30, 2024

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times

Oct 30, 2024
pulisher
Oct 30, 2024

LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St

Oct 30, 2024
pulisher
Oct 29, 2024

Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter

Oct 29, 2024
pulisher
Oct 28, 2024

LENZ reports positive Chinese study data for far-sightedness drug - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL

Oct 28, 2024
pulisher
Oct 28, 2024

Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World

Oct 28, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 28, 2024

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

Oct 28, 2024
pulisher
Oct 27, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com

Oct 27, 2024
pulisher
Oct 27, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian

Oct 27, 2024
pulisher
Oct 27, 2024

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com

Oct 27, 2024
pulisher
Oct 26, 2024

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat

Oct 26, 2024
pulisher
Oct 22, 2024

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance

Oct 22, 2024
pulisher
Oct 22, 2024

Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail

Oct 22, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com

Oct 21, 2024
pulisher
Oct 21, 2024

Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

One new option listing and ten option delistings on October 21st - TipRanks

Oct 21, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com

Oct 21, 2024
pulisher
Oct 18, 2024

Behind the Bell: LENZ Therapeutics - Nasdaq

Oct 18, 2024
pulisher
Oct 18, 2024

FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, - openPR

Oct 16, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail

Oct 16, 2024
pulisher
Oct 16, 2024

Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance

Oct 16, 2024
pulisher
Oct 16, 2024

Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada

Oct 16, 2024
pulisher
Oct 15, 2024

Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

TJX Companies (TJX-N) QuotePress Release - The Globe and Mail

Oct 15, 2024
pulisher
Oct 14, 2024

Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World

Oct 14, 2024

Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Capitalizzazione:     |  Volume (24 ore):